{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T01:37:46Z","timestamp":1776735466012,"version":"3.51.2"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"DOI":"10.1186\/s12969-026-01198-4","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T02:35:14Z","timestamp":1773369314000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of combined JAK1\/2 inhibition and cyclosporine in paediatric-onset Still\u2019s disease with lung involvement: a case report"],"prefix":"10.1186","volume":"24","author":[{"given":"Serena","family":"Palmeri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maddalena","family":"Lancieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacopo","family":"Ferro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Salvati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martino","family":"Cheli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Papa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Rosina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Volpi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerio Gaetano","family":"Vellone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Ravelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Gattorno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Caorsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"issue":"12","key":"1198_CR1","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1136\/ard-2024-225853","volume":"83","author":"AD Matteis","year":"2024","unstructured":"Matteis AD, Bindoli S, Benedetti FD, Carmona L, Fautrel B, Mitrovic S. Systemic juvenile idiopathic arthritis and adult-onset Still\u2019s disease are the same disease: evidence from systematic reviews and meta-analyses informing the 2023 EULAR\/PReS recommendations for the diagnosis and management of Still\u2019s disease. Ann Rheum Dis. 2024, Dec, 1;83(12):1748\u201361.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"1198_CR2","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1002\/art.41073","volume":"71","author":"GS Schulert","year":"2019","unstructured":"Schulert GS, Yasin S, Carey B, Chalk C, Do T, Schapiro AH, et al. Systemic juvenile idiopathic arthritis-associated lung disease: characterization and risk factors. Arthritis Rheumatol. 2019;71(11):1943\u201354.","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"1198_CR3","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1136\/annrheumdis-2019-216040","volume":"78","author":"VE Saper","year":"2019","unstructured":"Saper VE, Chen G, Deutsch GH, Guillerman RP, Birgmeier J, Jagadeesh K, et al. Emergent high fatality lung disease in systemic juvenile arthritis. Ann Rheum Dis. 2019, Dec, 1;78(12):1722\u201331.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1198_CR4","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s40272-023-00593-8","volume":"25","author":"C Towe","year":"2023","unstructured":"Towe C, Grom AA, Schulert GS. Diagnosis and management of the systemic juvenile idiopathic arthritis patient with emerging lung disease. Pediatr Drugs. 2023, Nov, 1;25(6):649\u201358.","journal-title":"Pediatr Drugs"},{"issue":"5","key":"1198_CR5","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1002\/acr.21889","volume":"65","author":"Y Kimura","year":"2013","unstructured":"Kimura Y, Weiss JE, Haroldson KL, Lee T, Punaro M, et al. Childhood arthritis rheumatology research alliance carra net investigators. Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2013, May;65(5):745\u201352. https:\/\/doi.org\/10.1002\/acr.21889.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"52","key":"1198_CR6","doi-asserted-by":"publisher","first-page":"15970","DOI":"10.1073\/pnas.1520779112","volume":"112","author":"MJ Ombrello","year":"2015","unstructured":"Ombrello MJ, Remmers EF, Tachmazidou I, Grom A, Foell D, Haas JP, et al. HLA-DRB1*11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. Proc. Natl. Acad. Sci. U. S. A. 2015, Dec, 29;112(52):15970\u201375.","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"issue":"3","key":"1198_CR7","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1136\/annrheumdis-2021-220578","volume":"81","author":"VE Saper","year":"2022","unstructured":"Saper VE, Ombrello MJ, Tremoulet AH, Montero-Martin G, Prahalad S, Canna S, et al. Drug hypersensitivity Consortium; INCHARGE Consortium. Severe delayed hypersensitivity reactions to IL-1 and IL-6 inhibitors link to common HLA-DRB1*15 alleles. Ann Rheum Dis. 2022, Mar;81(3):406\u201315.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"1198_CR8","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1002\/art.42099","volume":"74","author":"G Chen","year":"2022","unstructured":"Chen G, Deutsch GH, Schulert GS, Zheng H, Jang S, Trapnell B, et al. Identification of distinct inflammatory programs and biomarkers in systemic juvenile idiopathic arthritis and related lung disease by serum proteome analysis. Arthritis Rheumatol. 2022;74(7):1271\u201383.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"1198_CR9","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1093\/rheumatology\/kez284","volume":"59","author":"S Yasin","year":"2020","unstructured":"Yasin S, Solomon K, Canna SW, Girard-Guyonvarc\u2019h C, Gabay C, Schiffrin E, et al. IL-18 as therapeutic target in a patient with resistant systemic juvenile idiopathic arthritis and recurrent macrophage activation syndrome. Rheumatology. 2020, Feb, 1;59(2):442\u201345.","journal-title":"Rheumatology"},{"issue":"1","key":"1198_CR10","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s10875-022-01353-y","volume":"43","author":"JE Rood","year":"2023","unstructured":"Rood JE, Rezk A, Pogoriler J, Finn LS, Burnham JM, Josephson MB, et al. Improvement of refractory systemic juvenile idiopathic arthritis-associated lung disease with single-agent blockade of IL-1\u03b2 and IL-18. J Clin Immunol. 2023, Jan, 1;43(1):101\u201308.","journal-title":"J Clin Immunol"},{"issue":"11","key":"1198_CR11","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1016\/j.jaip.2024.07.002","volume":"12","author":"VE Saper","year":"2024","unstructured":"Saper VE, Tian L, Verstegen RHJ, Conrad CK, Cidon M, Hopper RK, et al. Interleukin (IL)-1\/IL-6-Inhibitor-associated drug reaction with eosinophilia and systemic symptoms (DReSS) in systemic inflammatory illnesses. J Allergy Clin Immunol Pract. 2024, Nov, 1;12(11):2996\u20133013.e7.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"7","key":"1198_CR12","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1002\/art.42137","volume":"74","author":"BA Binstadt","year":"2022","unstructured":"Binstadt BA, Nigrovic PA. The conundrum of lung disease and Drug hypersensitivity-like reactions in systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 2022;74(7):1122\u201331.","journal-title":"Arthritis Rheumatol"},{"key":"1198_CR13","doi-asserted-by":"crossref","unstructured":"C\u00f4te G, Quartier P, Belot A, Melki I, Hentgen V, Merlin E. The place of JAK inhibitors in systemic juvenile idiopathic arthritis with lung disease: French experience. Rheumatology. 2024, Oct, 24;keae589.","DOI":"10.1093\/rheumatology\/keae589"},{"issue":"3","key":"1198_CR14","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1002\/ppul.26821","volume":"59","author":"C Swanson","year":"2024","unstructured":"Swanson C, Khan EK, Cooper A, Ibarra M, Tam-Williams J. Pediatric systemic juvenile idiopathic arthritis-related lung disease: description of clinical cohort and review of management. Pediatr Pulmonol. 2024;59(3):724\u201333.","journal-title":"Pediatr Pulmonol"},{"issue":"7","key":"1198_CR15","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.3390\/jcm12072702","volume":"12","author":"F Zekre","year":"2023","unstructured":"Zekre F, Duncan A, Laurent A, Tusseau M, Pescarmona R, Collardeau-Frachon S, et al. Rescue of pap-mas in systemic JIA using janus kinase inhibitors, case report and systematic review. J Clin Med. 2023, Apr, 4;12(7):2702.","journal-title":"J Clin Med"},{"key":"1198_CR16","doi-asserted-by":"crossref","unstructured":"Bader-Meunier B, Hadchouel A, Berteloot L, Polivka L, B\u00e9ziat V, Casanova JL, et al. Effectiveness and safety of ruxolitinib for the treatment of refractory systemic idiopathic juvenile arthritis like associated with interstitial lung disease: a case report. Ann Rheum Dis. 2022, Feb, 1;81(2):e20.","DOI":"10.1136\/annrheumdis-2020-216983"},{"issue":"10","key":"1198_CR17","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1093\/rheumatology\/keaa242","volume":"59","author":"SE J\u00f8rgensen","year":"2020","unstructured":"J\u00f8rgensen SE, Christiansen M, H\u00f8st C, Glerup M, Mahler B, Lausten MM, et al. Systemic juvenile idiopathic arthritis and recurrent macrophage activation syndrome due to a CASP1 variant causing inflammasome hyperactivation. Rheumatology. 2020, Oct, 1;59(10):3099\u2013105.","journal-title":"Rheumatology"},{"issue":"4","key":"1198_CR18","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1172\/JCI129301","volume":"130","author":"de Jesus Aa","year":"2020","unstructured":"de Jesus Aa, Hou Y, Brooks S, Malle L, Biancotto A, Huang Y, et al. Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases. J Clin Invest. 2020, Apr, 1;130(4):1669\u201382.","journal-title":"J. Clin. Invest"},{"issue":"7","key":"1198_CR19","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1172\/JCI98814","volume":"128","author":"GAM Sanchez","year":"2018","unstructured":"Sanchez GAM, Reinhardt A, Ramsey S, Wittkowski H, Hashkes PJ, Berkun Y, et al. JAK1\/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest. 2018;128(7):3041\u201352. https:\/\/doi.org\/10.1172\/JCI98814.","journal-title":"J. Clin. Invest"},{"issue":"3","key":"1198_CR20","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1093\/rheumatology\/keab673","volume":"61","author":"EL Verweyen","year":"2022","unstructured":"Verweyen EL, Schulert GS. Interfering with interferons: targeting the JAK-STAT pathway in complications of systemic juvenile idiopathic arthritis (SJIA). Rheumatology. 2022, Mar, 1;61(3):926\u201335.","journal-title":"Rheumatology"},{"key":"1198_CR21","doi-asserted-by":"crossref","unstructured":"Marotte H, Tsou PS, Fedorova T, Pinney AJ, Lewis B, Koch AE. Blocking the janus-activated kinase pathway reduces tumor necrosis factor alpha-induced interleukin-18 bioactivity by caspase-1 inhibition. Arthritis Res Ther. 2014, Apr, 24;16(2):R102.","DOI":"10.1186\/ar4551"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-026-01198-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-026-01198-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-026-01198-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:52:27Z","timestamp":1776732747000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12969-026-01198-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1198"],"URL":"https:\/\/doi.org\/10.1186\/s12969-026-01198-4","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"assertion":[{"value":"8 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was conducted in accordance with the Declaration of Helsinki. Off-label baricitinib therapy was approved by the Ethics Committee of IRCCS Istituto Giannina Gaslini and Liguria Ethics Committee, Genoa (Italy). Written informed consent was obtained from the parents.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the parents.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The structure of this case report follows the CARE (Case Report) checklist, ensuring comprehensive reporting of the patient\u2019s clinical details and outcomes.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"CARE statement"}},{"value":"R.C., S.V and R.P received consultancy and speaker fee from SOBI. MG. received consultancy and speaker fee from Boheringer, Fresinius-Kabi, Kiniksa, Novartis and SOBI. S.P., M.L., J.F., P.S., M.C., S.R., V.G.V. declared no conflict of interest for this work. A.R. received consultancy and speaker fee from AbbVie, Angelini, BMS, Pfizer, Hoffman LaRoche, Novartis, Pfizer, Reckitt Benckiser.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27"}}